Institute of Nuclear Medicine and Department of Chemistry, University College London, London, UK.
Institute of Neurology, Department of Molecular Neuroscience, Queen Square Brain Bank, University College London, London, UK.
Alzheimers Dement. 2016 Nov;12(11):1116-1124. doi: 10.1016/j.jalz.2016.01.003. Epub 2016 Feb 15.
Aggregation of tau is a hallmark of many neurodegenerative diseases, and tau imaging with positron emission tomography (PET) may allow early diagnosis and treatment monitoring. We assessed binding of the PET tracer [F]AV-1451 in a range of dementias.
Phosphorimaging was used to quantify binding to postmortem brain tissue from 33 patients with different, histopathologically characterized, neurodegenerative dementias.
[F]AV-1451 showed high specific binding in cases with Alzheimer's disease (AD), moderate binding in Pick's disease and frontotemporal dementia with parkinsonism-17, and low but displaceable binding in corticobasal degeneration, progressive supranuclear palsy, non-tau proteinopathies, and in controls without pathology. Tracer binding did not correlate with tau load within disease groups.
[F]AV-1451 binds to tau in AD, and some other tauopathies. However, evidence for a non-tau binding site and lack of correlation between tracer binding and antibody staining suggest that reliable quantification of tau load with this tracer is problematic.
tau 聚集体是许多神经退行性疾病的标志，正电子发射断层扫描（PET）示踪 tau 成像可能允许早期诊断和治疗监测。我们评估了 PET 示踪剂 [F]AV-1451 在一系列痴呆症中的结合情况。
使用磷成像技术定量测定 33 名具有不同组织病理学特征的神经退行性痴呆患者死后脑组织中的结合情况。
[F]AV-1451 在阿尔茨海默病（AD）病例中显示出高特异性结合，在匹克病和额颞叶痴呆伴帕金森病 17 中显示出中等结合，在皮质基底节变性、进行性核上性麻痹、非 tau 蛋白病和无病理学对照中显示出低但可置换结合。示踪剂结合与疾病组内的 tau 负荷无关。
[F]AV-1451 在 AD 和其他一些 tau 病中与 tau 结合。然而，存在非 tau 结合位点的证据以及示踪剂结合与抗体染色之间缺乏相关性表明，使用该示踪剂可靠地定量 tau 负荷存在问题。
